Kansas City, MO (PRWEB) August 29, 2014
Dry Eye Disease is a common condition in which the eye does not produce enough tears to keep the surface of the eye sufficiently lubricated. It affects approximately 40 million people in the U.S. and 100 million people worldwide. In the U.S., less than 5% of the DED patient population has been diagnosed and is being treated, according to Healthcare Maintenance Organizations data. In its mild to moderate forms, it can impact vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision.
The TearLab Osmolarity System uses a novel lab-on-a-chip approach to measure tear osmolarity and can produce a sample-to-answer result in less than 30 seconds. TearLab eliminates the challenges that previously prevented accurate point-of-care testing for osmolarity.
Dr. Stephen Wiles, Medical Director at Perfect Sense, and an area leader in the field of Dry Eye management, said, “Today’s announcement further demonstrates our commitment to building a practice that is dedicated to providing the highest quality of care using advanced ophthalmic diagnostic techniques and treatments. Equipped with the TearLab Osomolarity System, we can now use quantitative data at the point of care to aid in the diagnosis of DED and to improve our ability to manage these patients.”
About Perfect Sense Eye Centers
Perfect Sense Eye Centers (http://www.perfect2020.com) are home to some of the most highly regarded ophthalmologists and optometrists in the Kansas City area. In order to help all of their patients achieve their best possible vision, the eye care staff of Perfect Sense use advanced technologies and techniques. Combined with their outstanding surgical skills and dedication, this treatment approach has allowed thousands of Kansas City eye care patients realize their dreams of clear vision.
About TearLab Corporation
TearLab Corporation (http://www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.